drug discovery Archives
May. 5, 2016—The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods.
Dec. 10, 2015—Vanderbilt University Medical Center and Ono Pharmaceutical Group, an international company based in Japan, have signed a drug discovery agreement.
Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.
Nov. 21, 2014—A family of single-celled organisms that thrive in environments too extreme for most other species to survive may be an untapped source of new antibacterial drugs.
Nov. 20, 2014—A receptor in the brain that regulates appetite and body weight has now been found in L cells, key regulatory cells in the gut, providing the pharmaceutical industry with a novel drug target for both obesity and diabetes, a Vanderbilt University-led research team reported this week.
Sep. 4, 2014—A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways.